HomeAI · summaries
Storia in 2 fonti
Roche’s incretin shot works in mid-stage trial in type 1 diabetes
Roche's acmopatide cut A1C by 0.34% and reduced insulin use by 15% in a Phase 2 trial in type 1 diabetes patients with obesity.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Roche’s incretin shot works in mid-stage trial in type 1 diabetes
Roche's acmopatide cut A1C by 0.34% and reduced insulin use by 15% in a Phase 2 trial in type 1 diabetes patients with obesity.
- ·
healio.com
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented…
- ·
Roche wants the best of both worlds with amylin-incretin combo strategy
Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly…